… This grant builds upon the research from a prior grant: Preferential Targeting of Subpopulations … dyskinesia that arises in Parkinson’s disease (PD) patients from prolonged treatment with levodopa. Data gathered in the …

… This grant builds upon the research from a prior grant: Characterization of NPT001-mediated … of NPT088 in PD models was also carried out, and the data from this study show that NPT088 has similar half-life and …

… two broad categories: targets for therapies to alleviate dyskinesias, the excessive, uncontrollable movements brought … (mGluR5) could prevent the development of levodopa-induced dyskinesias. The current award will allow her to take this … the MPTP-lesioned NHP Model for Treating Levodopa-induced Dyskinesia” Erwan Bezard, PhD, INSERM, France “Validation of …

… community to continue to accelerate research. Support from our donors allows us to advance research to better … funded one project at $1.4 million. Through prior funding from MJFF, Johannes Levin, MD, Armin Giese, MD, and the team …

… Foundation (MJFF). With the support of early investments from MJFF, Kynmobi is the second Foundation-funded PD drug … for people with Parkinson’s who experience 'off.’ We know from our research and discussions with the Parkinson’s …

… role of PINK1 and parkin proteins in protecting brain cells from damage (neuroprotection). This includes studies … the generation of new ideas and consolidating information from the field by bringing together the community of …